INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2016

Lowering LDL-C via statins and nonstatin therapies upregulating LDL receptors is associated with similar reductions in major vascular events.

A meta-regression analysis of 49 trials (312,175 participants) evaluated cardiovascular risk reductions across 9 approaches to lowering LDL-C. The relative risk of major vascular events per 1-mmol/L (38.7-mg/dL) reduction in LDL-C was 0.77 (95% CI, 0.71-0.84) for statins and 0.75 (95% CI, 0.66-0.86) for nonstatin interventions upregulating LDL receptors (diet, bile acid sequestrants, ileal bypass, and ezetimibe; between-group difference P = .72). For these 5 therapies combined, the RR was 0.77 (95% CI, 0.75-0.79). Achieved LDL-C levels were significantly associated with lower rates of major coronary events in both primary (1.5% lower rate per 1-mmol/L reduction) and secondary prevention trials (4.6% lower rate per 1-mmol/L reduction).

Study type
Systematic review and meta-regression of RCTs
Who was studied
312,175 participants across 49 randomized clinical trials
What was measured
Relative risk of major vascular events per absolute reduction in LDL-C; 5-year rate of major coronary events

THE PAPER

Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.

Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. JAMA, 2016.

PubMed 27673306 ↗DOI 10.1001/jama.2016.13985 ↗

Heart & arteries

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.